Chemosensitivity/Resistance Assay Included As Part of the NCCN Principles of Chemotherapy
March 2, 2010
Precision Therapeutics announced that The National Comprehensive Cancer Network(R) (NCCN) recently updated the NCCN Clinical Practice Guidelines for Oncology (NCCN Guidelines) for Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer to include the use of chemosensitivity/resistance assays as part of the Principles of Chemotherapy section. While the NCCN Guidelines state that this technology is not intended to supplant standard of care chemotherapy, chemosensitivity/resistance assays are being used in some NCCN Member Institutions for decisions related to future chemotherapy ...more
« WV Teachers to Attend Carnegie Learning Math Academy | | TOA Technologies Appoints European President »
